Enhancement patterns of prostate cancer in dynamic MRI

European Radiology - Tập 13 - Trang 925-930 - 2003
Paolo Preziosi1, Antonio Orlacchio1, Guido Di Giambattista1, Paolo Di Renzi1, Luigi Bortolotti1, Alfredo Fabiano2, Enrico Cruciani3, Patrizio Pasqualetti4
1Department of Radiology, AFaR-CRCCS, Fatebenefratelli Hospital, Isola Tiberina, 00186 Rome, Italy,
2Department of Pathology, AFaR-CRCCS, Fatebenefratelli Hospital, Isola Tiberina, 00186 Rome, Italy,
3Department of Urology, AFaR-CRCCS, Fatebenefratelli Hospital, Isola Tiberina, 00186 Rome, Italy,
4Department of Statistics, AFaR-CRCCS, Fatebenefratelli Hospital, Isola Tiberina, 00186 Rome, Italy,

Tóm tắt

Our objective was to analyze fast-field-echo dynamic subtracted (FFE/DS) MRI data in prostate cancer, in order to recognize enhancement patterns of tumoral tissue in comparison with non-tumoral peripheral prostatic tissue. Eleven consecutive patients with prostate cancer were proposed for radical prostatectomy. Before surgery, all patients underwent endorectal coil MRI examination. In addition to standard sequences, a dynamic study was performed by FFE/DS to evaluate tumoral behavior after Gd-DTPA rapid infusion. Analysis of the imaging was made by the means of the time/signal intensity curve obtained during early contrast medium enhancement, sampling both the abnormal enhancing focal area and the opposite lobe at the level of the main prostatic tissue. A focal area of increased enhancement was observed in the site of the tumor in all cases. The time/intensity curve sampled on this area and compared with the opposite lobe demonstrated a high confidence interval of the difference of the data: mean tumor maximal intensity 1331 (SD 187) vs normal 470 (SD 139) and mean tumor rise time 103 s (SD 30) vs normal 250 (SD 38; p<0.01). In tumoral tissue, the enhancement percentage of signal intensity (SI%=pre-contrast minus post-contrast/pre-contrast ×100) was 316.7%. At FFE/DS, there is a typical behavior of the time/intensity curve of contrast enhancement in prostatic cancer that might be employed in diagnosis of the disease.